TDOC (TDOC) Form 144: Director sales and proposed resale of 2,500 shares
Teladoc Health, Inc. (TDOC) has filed a Form 144 notice disclosing a proposed resale of 2,500 shares of common stock stemming from restricted stock vesting dated March 19, 2025. The filing also details three recent open-market sales by Kelly M. Bliss on June 2, June 29, and July 1, 2026, totaling 7,679, 2,500, and 2,500 shares respectively, with their associated proceeds. This Form 144 serves to provide public notice of these security transactions.
Teladoc Health (TDOC) Faces Flat Sales, Is The Recent Rally Already Priced In?
Teladoc Health (TDOC) is experiencing stagnant sales and falling average revenue per user, yet its stock has seen a significant rally. While one valuation narrative suggests TDOC is overvalued at $9.20 against a $7.40 fair value, another perspective notes its P/S ratio of 0.7x is well below industry averages, raising questions about whether the recent price surge has already accounted for future growth or if the market has overreacted negatively.
Teladoc gives new BetterHelp product chief 50,000 shares
Teladoc Health (NYSE: TDOC) has granted 50,000 restricted stock units to David Packles, the new Head of Product for BetterHelp, effective July 1, 2026. These RSUs will vest one-third after one year, with the remainder vesting quarterly over the subsequent two years. This inducement award, made under NYSE Rule 303A.08, aims to incentivize and retain key leadership as Teladoc continues to invest in its virtual care offerings.
Teladoc Health Announces Employee Inducement Award under NYSE Rule 303A.08
Teladoc Health, Inc. announced an inducement award to David Packles, the new Head of Product for BetterHelp. This award, effective July 1, 2026, consists of 50,000 restricted stock units that will vest over three years based on continued service. The award was granted under the Teladoc Health, Inc. 2023 Employment Inducement Incentive Award Plan, adhering to NYSE Rule 303A.08.
Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Teladoc (TDOC)
Truist Financial analysts have maintained "Hold" ratings on both Incyte (INCY) and Teladoc (TDOC). For Incyte, analyst Srikripa Devarakonda cited a Moderate Buy consensus with a slight downside from its average price target, while Jailendra Singh maintained a Hold rating for Teladoc, also noting a projected downside from its average price target. These ratings suggest analysts are neither significantly bullish nor bearish on the short-term prospects of these healthcare stocks.
Teladoc Health: A Rally Built on Shaky Foundations
Teladoc Health's stock has surged, nearing 52-week highs, despite underlying financial woes like declining revenue in its BetterHelp segment and persistent unprofitability. The company faces significant challenges, including a heavy debt load and a negative revenue growth rate for FY2025. Wall Street analysts maintain a cautious "Hold" rating with a median price target significantly below the current trading price, suggesting the rally is built on speculative interest rather than fundamental strength.
Teladoc's Recovery Story Is Starting to Take Shape. Should You Buy the Stock?
Teladoc Health's stock is up 28% year-to-date, outperforming the S&P 500, despite a 2% revenue decline in Q1 and continued unprofitability. The market is reacting positively to developments like increased insurance coverage for BetterHelp and international expansion, alongside AI initiatives that improve efficiency. However, the company still faces challenges including a competitive virtual therapy market and potential complexities with global expansion, making its stock risky despite recent progress.
Insider Sell: Kelly Bliss Sells 2,500 Shares of Teladoc Health I
Kelly Bliss, President, U.S. Group Health at Teladoc Health Inc (TDOC), sold 2,500 shares on July 1, 2026, reducing her holdings to 87,378 shares. Over the past year, she has sold 48,608 shares with no purchases, contributing to a pattern of 1 insider buy and 31 insider sells at Teladoc. The stock was trading at $9, making it fairly valued with a price-to-GF-Value ratio of 1.07.
Teladoc Health (NYSE: TDOC) exec sells $22,500 under 10b5-1 plan
Teladoc Health executive Kelly Bliss, President, U.S. Group Health, sold 2,500 shares of common stock for $22,500 at $9.00 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025, and leaves her with 87,378 shares. The sale is considered routine and does not necessarily reflect a change in insider sentiment regarding the stock.
TDOC (NYSE) insider sale notices: 10,179 shares sold in June 2026
Teladoc Health, Inc. (TDOC) filed a Form 144, reporting sales of 10,179 shares in June 2026, totaling $79,817.73. The filing also detailed restricted stock vesting events in March and June 2025. These disclosures are routine for Form 144 filings and provide transparency on insider transactions.
Teladoc Health president Kelly Bliss sells $21,250 in common stock By Investing.com
Kelly Bliss, President of U.S. Group Health at Teladoc Health, recently sold 2,500 shares of the company's common stock for a total of $21,250, following a 10b5-1 trading plan. The sale occurred after the stock experienced a 10% gain over the past week and a 21% return year-to-date. Teladoc Health also announced new partnerships with Walmart and developments for its BetterHelp platform, alongside updated price targets from analysts.
Teladoc Health (TDOC) executive sells 2,500 shares in 10b5-1 trade
Teladoc Health executive Kelly Bliss, President, U.S. Group Health, sold 2,500 shares of common stock at $8.50 per share on June 29, 2026, totaling $21,250. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025. Following the sale, Bliss directly holds 89,878 shares of Teladoc Health common stock.
Teladoc Health, Inc.(NYSE:TDOC) dropped from Russell Small Cap Comp Growth Benchmark
Teladoc Health, Inc. (NYSE:TDOC) has been removed from the Russell Small Cap Comp Growth Benchmark, along with the Russell 2500 Growth, Russell 2000 Growth, and Russell 3000E Growth Benchmarks. This news follows several recent updates for the company, including making its services available through Walmart's Better Care Services platform and reporting its Q1 2026 earnings. The company provides virtual healthcare services through its Integrated Care and BetterHelp segments.
Teladoc Health (TDOC) Faces Broad Russell Index Exit Is Its Investment Narrative Being Rewritten?
Teladoc Health (TDOC) has been removed from several Russell Growth indexes, including the Russell 2000, 2500, 3000, 3000E, and Small Cap Composite Growth indexes, which could lead to mechanical selling by index-linked funds. While this may increase share price volatility, the underlying investment narrative still hinges on the company's ability to deepen its role in virtual chronic disease and mental health management despite unprofitability. The real risk for investors involves persistent reimbursement and margin pressure, with current forecasts projecting $2.6 billion revenue and $173.1 million earnings by 2029, suggesting a 12% downside to its current price based on a $7.40 fair value.
Teladoc (TDOC) Moves 6.1% Higher: Will This Strength Last?
Teladoc (TDOC) shares recently gained 6.1% due to increased trading volume and investor optimism regarding the company's growth prospects and turnaround strategy. While the company is focusing on expanding its virtual care platform and improving efficiency, its upcoming earnings report is projected to show a loss per share and a decrease in revenue. The stock currently holds a Zacks Rank #3 (Hold), and its future strength depends on trends in earnings estimate revisions.
Teladoc Health, Inc.(NYSE:TDOC) dropped from Russell 2500 Growth Benchmark
Teladoc Health, Inc. (NYSE: TDOC) has been removed from the Russell 2500 Growth Benchmark. This news follows a series of similar removals from other Russell indices, including the Russell Small Cap Comp Growth, Russell 2000 Growth, and Russell 3000E Growth Benchmarks, all announced on June 29, 2026. The virtual healthcare provider's stock performance and underlying metrics likely led to these changes in its index inclusions.
Affiliate files Form 144 to sell 2,500 restricted shares (TDOC)
An affiliate of Teladoc Health (TDOC) has filed a Form 144 to sell 2,500 restricted shares that vested on June 1, 2025. The filing also indicates that 7,679 shares were sold in the prior three months for over $58,000. Fidelity Brokerage Services LLC is listed as the broker for the proposed resale.
Teladoc Health (TDOC) Faces Broad Russell Index Exit Is Its Investment Narrative Being Rewritten?
Teladoc Health (TDOC) was recently removed from several Russell Growth indexes, including the Russell 2000 and 3000, which could lead to mechanical selling by index-linked funds and impact its institutional ownership. While this exit adds share price volatility, it doesn't alter Teladoc's core investment narrative centered on virtual care adoption and partnerships like Walmart Better Care Services. Investors are advised to consider the long-term implications of reimbursement and margin pressures on its path to profitability, as analysts have varying forecasts for its revenue and earnings.
Enterprise value to revenue forward of Teladoc Health, Inc. – NYSE:TDOC
The article presents financial data for Teladoc Health, Inc. (NYSE: TDOC), specifically focusing on its enterprise value to revenue forward metric. It appears to be a financial data point provided by TradingView, indicating a quantitative measure for the company over a specific period.
Price to sales forward of Teladoc Health, Inc. – NYSE:TDOC
This article provides financial information for Teladoc Health, Inc. (NYSE: TDOC), specifically focusing on its forward price-to-sales ratio. It details the company's ticker symbol on the New York Stock Exchange and touches upon various data sources and copyright information related to the financial data presented.
Teladoc Health, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 1 Sh
This page provides financial actuals and estimates for Teladoc Health, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 1 Sh (BMFBOVESPA:T2DH34). Users can explore reported financial data and analyst estimates, comparing actual results with various estimates and visualizing trends over time across income statements, balance sheets, and cash flow statements. The platform emphasizes that the information is not investment advice and encourages users to conduct their own research.
Dr. Ethan Berke: Most Influential Clinical Executives 2026
Dr. Ethan Berke, the Chief Medical Officer of Teladoc Health, has been recognized as one of the "Most Influential Clinical Executives 2026" by Modern Healthcare. This recognition highlights his significant role and influence in the clinical executive field.
Teladoc Health, Inc. Actuals & Estimates (NYSE:TDOC)
This article provides financial actuals and estimates for Teladoc Health, Inc. (NYSE:TDOC), including its current stock price, volatility, market capitalization, and analyst forecasts. It details the company's past earnings and revenue performance, future earnings report date, and an overview of its financial statements. The article also touches upon technical analysis ratings for TDOC stock.
Teladoc Health, Inc. 실제 및 예상 (MUN:4LL)
This article provides an overview of Teladoc Health, Inc. (MUN:4LL) financial actuals and analyst estimates. It includes information on the company's stock ticker, future price forecasts, historical highs and lows, upcoming earnings reports, and key financial metrics such as earnings per share, revenue, net income, and EBITDA. The article also confirms that Teladoc Health, Inc. does not pay dividends and details its employee count.
Teladoc (TDOC) Ascends While Market Falls: Some Facts to Note
Teladoc (TDOC) saw a 1.56% increase in its stock price, outperforming the S&P 500's loss, with a 16.69% rise over the past month. Despite a projected decrease in Q2 earnings per share and revenue, analysts' estimates for the company's annual performance show anticipated growth. Teladoc currently holds a Zacks Rank #3 (Hold).
Teladoc (TDOC) Ascends While Market Falls: Some Facts to Note
Teladoc (TDOC) recently closed at $7.81, showing a 1.56% increase, outperforming the S&P 500's loss. Over the past month, TDOC stock climbed 16.69%, significantly exceeding the Medical sector's gain. Analysts anticipate Teladoc's upcoming earnings per share to be -$0.24, with revenue projected at $614.69 million for the quarter.
Form 13G Teladoc Health For: 22 June By Investing.com
This article from Investing.com announces a Form 13G filing for Teladoc Health pertaining to June 22. It provides no further details beyond this announcement, merely stating the filing has occurred. The rest of the content includes market data and news headlines unrelated to the Form 13G.
Voss entities and Travis Cocke report 9.03M shares in Teladoc (TDOC)
Voss entities and Travis Cocke have reported a beneficial ownership of 9.03 million shares in Teladoc Health (TDOC), representing approximately 5.0% of the company's outstanding shares. This disclosure, made via a SCHEDULE 13G SEC filing, details holdings across Voss Value Master Fund, Voss Value-Oriented Special Situations Fund, Voss Advisors GP, Voss Capital, and Travis W. Cocke directly. The reported holdings include 700,000 shares underlying currently exercisable call options and are based on 180,513,087 shares outstanding as of April 23, 2026.
Teladoc Health extends rally to seventh straight session
Teladoc Health (TDOC) has extended its rally to a seventh consecutive session. The stock closed up 2.7% at $10.66 today, bringing its seven-day gain to 12% and its year-to-date performance to +28%. This positive movement follows a period of significant losses, as the stock had previously plummeted 79% in 2022 and 22% in 2023.
Teladoc: Stagnant Growth Suggests Telehealth Still A Solution Waiting For A Problem (TDOC)
Teladoc Health, Inc. (TDOC) has been upgraded from a "Sell" to a "Hold" rating due to slight strategic pivots aimed at new growth avenues, despite stagnant revenues. The company's Q1 2026 results showed a 2% year-over-year revenue decrease, though it remains EBITDA and cash flow positive. Key initiatives like a Walmart partnership and BetterHelp's insurance rollout are being watched as important tests for boosting utilization and top-line performance.
Teladoc Health Inc (TDOC) Earnings Forecast: Future EPS & Revenue Growth Estimates
Teladoc Health Inc (TDOC) has an current earnings forecast score of 6.67, ranking 52 out of 76 in its industry, with an average price target of $8.50. Analysts largely recommend a "hold" for the stock, with 26 analysts contributing to the rating. The company's expected revenue for the next quarter is $614.91M, and its EPS for the previous quarter was -$0.14, with the next quarter's EPS projected at -$0.25.
Is Conflicting Earnings Signals And Brighter Estimates Altering The Investment Case For Teladoc Health (TDOC)?
Teladoc Health is facing conflicting signals, with analysts projecting a 26.32% year-over-year earnings decline for its upcoming report, yet recent estimate revisions suggest healthier near-term business conditions and improved profitability expectations. This combination suggests that while short-term earnings remain a risk, the focus for Teladoc's investment narrative is shifting towards evidence of margin progress and successful partnerships like the one with Walmart's Better Care Services platform. The stock's fair value is estimated at $7.12, indicating a 3% downside from its current price, though some analysts are far more optimistic about its long-term potential.
Is Conflicting Earnings Signals And Brighter Estimates Altering The Investment Case For Teladoc Health (TDOC)?
Teladoc Health (TDOC) is facing conflicting signals, with analysts projecting a 26.32% year-over-year earnings decline for its upcoming report, yet recent estimate revisions indicate healthier near-term business conditions and improving profitability expectations. The company's investment narrative relies on virtual care becoming core to patient management and Teladoc achieving sustainable profitability, with recent partnerships like the one with Walmart's Better Care Services platform aiming to expand consumer access and visit volumes. Despite these promising developments, investors should be aware of a less obvious risk concerning BetterHelp’s shift toward lower-margin insurance-based revenue.
Is Conflicting Earnings Signals And Brighter Estimates Altering The Investment Case For Teladoc Health (TDOC)?
Analysts are projecting a 26.32% year-over-year earnings decline for Teladoc Health (TDOC) ahead of its upcoming report, yet recent estimate revisions suggest improving near-term business conditions. This conflicting outlook, coupled with strategic partnerships like the one with Walmart, highlights the importance of observing margin progress as a key catalyst. Despite an anticipated earnings decline, an analysis forecasts Teladoc reaching $2.6 billion in revenue and $164.1 million in earnings by 2029, suggesting a potential fair value of $7.12.
Why Has Teladoc (TDOC) Stock Underperformed the Broader Market
Teladoc Health (TDOC) stock has significantly underperformed the broader market, trading near its 52-week low due to persistent revenue growth challenges and intense competition in the telehealth sector. Despite recent earnings beats, cautious forward guidance and concerns over declining user engagement are weighing on investor sentiment. The company's debt profile and ongoing goodwill impairment charges, stemming from past acquisitions, also contribute to investor apprehension.
Teladoc (NYSE: TDOC) CEO exercises stock units, sells shares for taxes
Teladoc Health, Inc. CEO Charles DiVita III exercised restricted and performance stock units, acquiring 42,802 common shares. He subsequently sold 18,074 shares at $6.942 each to cover tax withholding obligations related to the vesting of these awards. After these transactions, DiVita directly holds 414,622 shares of Teladoc common stock, indicating a routine compensation event rather than a discretionary sale for liquidity.
Teladoc stock surges 69% after Fair Value models spotted opportunity
Teladoc Health (NYSE:TDOC) stock surged 69% after InvestingPro's Fair Value analysis identified it as significantly undervalued in February 2026. The analysis, which calculates intrinsic value through multiple valuation methodologies, accurately predicted the stock's remarkable return from $4.68 to $7.34. The company's rally was driven by improved fundamentals and a new partnership with Walmart, and InvestingPro's current analysis suggests further upside potential.
Teladoc Health (TDOC) Stock After 70% Three-Year Slide Is The Market Overreacting
Teladoc Health (TDOC) has seen its stock price decline by over 70% in three years, raising questions about whether it is undervalued. A Discounted Cash Flow (DCF) analysis suggests the stock could be undervalued by 46.4%, with an intrinsic value of $13.70 per share compared to the current $7.34. Additionally, its Price/Sales ratio of 0.53x is significantly below the industry average, further indicating potential undervaluation, though both bull and bear case narratives present differing fair value estimates.
Fidelity files 18,074-share Form 144 notice; TDOC (NYSE: TDOC)
Fidelity Brokerage Services LLC has filed a Form 144 notice for the proposed sale of 18,074 shares of Teladoc Health, Inc. (TDOC) common stock. These shares are associated with a restricted stock vesting event that occurred on June 10, 2026, and are considered compensation issued by the company. The filing also notes previous sales by Charles Divita of 27,731 shares on March 11, 2026, and 19,132 shares on June 2, 2026.
What better health looks like in the digital era
This article features Teladoc Health's vision for connected care, as articulated by their Chief Medical Officer, Ethan Berke. It explores how digital solutions are shaping the future of healthcare, focusing on virtual care quality and access. The discussion is presented within the context of advancements in the digital era.
A Look At Teladoc Health (TDOC) Valuation After New Walmart Virtual Care Partnership
Teladoc Health (TDOC) has expanded its virtual care services onto Walmart’s Better Care Services platform, giving it access to a broader retail customer base. Despite a recent share price dip, its 90-day return shows improved sentiment, and it is currently undervalued by about 48% against a fair value of $7.12. The underlying narrative for this valuation highlights Teladoc's investment in product innovation and its potential to capture growing demand for digital chronic disease management and cost-effective care.
A Look At Teladoc Health (TDOC) Valuation After New Walmart Virtual Care Partnership
Teladoc Health (TDOC) is gaining attention after expanding its virtual care services onto Walmart’s Better Care Services platform. Despite a recent cool-down in share price momentum, the company is seen as having a large intrinsic discount. The partnership and Teladoc's ongoing product innovation are expected to drive long-term revenue and enrollment growth, though risks like profitability and market competition are noted.
What better health looks like in the digital era
This article features an executive conversation with Ethan Berke, MD, MPH, Chief Medical Officer and Senior Vice President of Integrated Care at Teladoc Health. Dr. Berke discusses Teladoc Health's vision for connected care and what better health entails in the digital era, focusing on virtual care quality and access.
Here's Why Investors Should Hold on to Teladoc Health Stock for Now
Teladoc Health (TDOC) is recommended as a stock to hold due to its strong performance in the Integrated Care and International operations segments, improved cost discipline, and strategic acquisitions, despite challenges in its BetterHelp segment and intense market competition. The company carries a Zacks Rank #3 (Hold) and shows a clear path towards profitability with projected adjusted EBITDA of $267-$306 million for 2026. Investors should consider Teladoc's business tailwinds against the risks posed by the underperforming BetterHelp segment and its current unprofitability.
Here's Why Investors Should Hold on to Teladoc Health Stock for Now
Teladoc Health (TDOC) is recommended as a stock to hold due to its strong performance, attractive valuation, and growth in its Integrated Care and international segments. Despite challenges in its BetterHelp segment and ongoing unprofitability, cost discipline and product innovation suggest a clearer path to profitability. The article suggests investors monitor the company's progress and consider its competitive landscape.
Insider Sell: Fernando Rodrigues Sells 9,572 Shares of Teladoc H
Fernando Rodrigues, President of BetterHelp, sold 9,572 shares of Teladoc Health Inc (TDOC) on June 3, 2026, bringing his total ownership to 0 shares. This transaction is part of a trend of 28 insider sells against only 1 insider buy over the past year for TDOC. Despite the sales, Teladoc Health Inc is considered modestly undervalued with a price-to-GF-Value ratio of 0.88, at a trading price of $7.4 per share.
Teladoc (TDOC) BetterHelp president sells 9,572 shares under 10b5-1 plan
Fernando M. Rodrigues, President of BetterHelp (a Teladoc Health subsidiary), sold 9,572 shares of Teladoc Health common stock at $7.40 per share under a pre-arranged Rule 10b5-1 trading plan. This transaction, executed on June 3, 2026, reduced his direct holdings in the company to zero shares. The sale totaled approximately $70,833.
Teladoc Health (TDOC) Is Up 7.6% After Walmart Expands $89 Virtual Care Visits Integration – Has The Bull Case Changed?
Teladoc Health (TDOC) shares rose 7.6% after Walmart expanded its integration to include Teladoc's virtual urgent care, dermatology, and nutrition services for $89 cash-pay visits, building on previous mental health service integration. This move aims to increase visit volumes and explore flexible pricing models, which is crucial for Teladoc's path to profitability. While it could improve Teladoc's investment narrative, challenges like compliance costs and the need for improved margins in chronic care and BetterHelp remain key considerations for investors.
Teladoc Health (TDOC) Is Up 7.6% After Walmart Expands $89 Virtual Care Visits Integration – Has The Bull Case Changed?
Teladoc Health (TDOC) shares rose 7.6% after Walmart expanded the integration of Teladoc's virtual care services, including urgent care, dermatology, and nutrition, on its Better Care Services platform for $89 cash-pay visits. This deepens Teladoc's presence in Walmart's health ecosystem and aims to increase visit volumes and pricing flexibility. While analysts remain divided on Teladoc's path to profitability and fair value, the expanded partnership is seen as a positive development for its investment narrative.
Teladoc (TDOC) BetterHelp president reports RSU vesting and tax-related share sale
Fernando M. Rodrigues, President of BetterHelp at Teladoc Health, Inc., recently reported the vesting of 15,249 restricted stock units into Teladoc common stock. To cover the associated tax withholding obligation, Rodrigues sold 5,677 shares at an average price of $7.627 per share. Following these transactions, he directly holds 9,572 shares of Teladoc common stock, in addition to remaining unvested restricted stock units.
